Endoglin in head and neck neoplasms

Małgorzata Litwiniuk-Kosmala; Maria Makuszewska; Małgorzata Czesak

doi:10.3389/fmed.2023.1115212

Endoglin in head and neck neoplasms

Front Med (Lausanne). 2023 Feb 10:10:1115212. doi: 10.3389/fmed.2023.1115212. eCollection 2023.

Authors

Małgorzata Litwiniuk-Kosmala¹, Maria Makuszewska¹, Małgorzata Czesak¹

Affiliation

¹ Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Warsaw, Warsaw, Poland.

Abstract

Tumors of the head and neck region form a heterogeneous group of pathologies, including various benign lesions and malignant neoplasms. Endoglin, also known as CD105, is an accessory receptor for transforming growth factor beta (TGF-β), that regulates angiogenesis, both under physiological and pathological conditions. It is highly expressed in proliferating endothelial cells. Therefore, it is considered as a marker of tumor-related angiogenesis. In this review we discuss the role of endoglin as a possible marker of carcinogenesis, as well as a potential target for antibody-based therapies in the neoplasms of the head and neck region.

Keywords: angiogenesis; endoglin; head and neck tumors; paraganglioma; salivary gland tumors.

Publication types

Review